# A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

> **NCT04711148** · PHASE2 · UNKNOWN · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 160 (estimated)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **OTHER:** placebo
- **DRUG:** orelabrutinib

## Key facts

- **NCT ID:** NCT04711148
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2026-02-25
- **Final completion:** 2026-03-01
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2023-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04711148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04711148, "A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04711148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*